XILAM
14.5.2018 19:00:11 CEST | Business Wire | Press release
Regulatory News:
The growth of the audience (number of views) garnered by Xilam’s (Paris:XIL) programmes on YouTube has been accelerating over recent months.
While the number of views rose 21% in 2017, Xilam has seen an impressive 79% increase in the number of views between November 2017 and April 2018, in comparison to the same period last year. Based on this trend, Xilam’s programmes, which were viewed 2.6 billion times on YouTube in 2017, are expected to garner close to 4 billion views in 2018 .
Even more remarkably, revenues over this same six-month period increased 126%. This differential can be explained by a substantial improvement in the monetisation factors.
In addition to the viewing figures, the number of subscribers is also increasing quickly across Xilam’s channels, rising 50% over the same six-month period. Xilam is anticipating reaching close to 5 million total subscribers by the end of 2018 (in comparison to 2.2 million in December 2017). The official Zig and Sharko channel will, by then have reached the same number of subscribers as Oggy & the Cockroaches .
This progress is due to a number of factors:
- The remarkable work by Xilam’s digital team in managing Xilam’s YouTube channels, creating new channels as well as increasing the volume of content being posted (x3 in comparison to the previous year). The teams have also developed a significant expertise in SEO (Search Engine Optimization).
- In a number of developed western markets, including the US, the most successful Xilam programmes are included in Google Preferred, the program that aggregates YouTube's top content into easy-to-buy packages for brand advertisers.
- While revenues made solid gains in Asia-Pacific, they rose even more quickly in North America. This is the result of the recent release of new seasons of Oggy & the Cockroaches and Zig and Sharko on Netflix and Amazon. This massive exposure boost has had a spectacular impact on revenues from YouTube, in particular on the official Zig and Sharko channel which now generates 45% of its revenues in the United States.
Xilam proves to be at the very heart of the digital transformation and the globalisation it is generating. This range of linear and non-linear media is combining forces on a global scale to support Xilam’s premium programmes, and this convergence is benefiting everyone.
This trend will certainly underpin growth in Xilam’s Catalogue revenue.
Marc du Pontavice, Chairman and CEO of Xilam, said: “I am delighted with both the amazing work carried out by Xilam’s teams, and the essential support and guidance provided by our partners at YouTube and YouTube Kids. These platforms enhance the accessibility of Xilam’s programmes worldwide, offering children the chance to have high-quality entertainment at their fingertips .”
Gregory Dray, Director, Head of Kids/Family and Learning, EMEA, Google/YouTube added: “Xilam's universally loved programs have naturally found a unique place on global platforms like YouTube and YouTube Kids. The success of Xilam’s content is a testament to its quality and universality. We are also delighted to see Xilam's commitment to developing a specific expertise in audience development, channel management and programming strategies. As such, the company is well positioned to fully benefit from the rapid growth of YouTube Kids around the world.”
About Xilam
Xilam is one of Europe’s leading animation companies, creating, producing and distributing original children’s and family entertainment content across TV, film and digital media platforms.
Founded in 1995 by Marc du Pontavice, Xilam owns a catalogue of more than 2,000 animated episodes and three feature films including strong brands such as Oggy & the Cockroaches, Zig & Sharko, The Daltons and its first preschool series, Paprika.
Broadcast in over 190 countries on all the major TV networks and digital platforms, in particular garnering over 2.6 billion views on YouTube in 2017, Xilam’s programme catalogue makes the company one of the top global content providers in animation.
Xilam employs more than 400 people, including 300 artists, who are based across its four studios located in Paris, Lyon, Angoulême and Ho-Chi-Minh City in Vietnam.
Xilam is listed on Compartment B of Euronext Paris
PEA-eligible
SRD
long-eligible
ISIN code: FR0004034072 / Ticker: XIL
86-90, rue Notre-Dame de Nazareth – 75003 PARIS – Tel: +33 (0)1 40 18 72
00 – Fax: +33 (0)1 40 03 02 26
A société anonyme
(public
limited company) with share capital of EUR 446,500 Paris Trade and
Companies Register (RCS): 423 784 610 – SIRET: 423 784 610 00044 – APE
921 A
View source version on businesswire.com: https://www.businesswire.com/news/home/20180514006096/en/
Contact:
Contacts at Xilam
Marc du Pontavice, +33 1 40 18 72 00
Chairman
and CEO
or
Contacts Google/YouTube
Google/YouTube
– Press Service
presse-fr@google.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
